TIMOTHY G BERGER

Allopathic & Osteopathic Physicians|Dermatology SAN FRANCISCO, CA NPI 1124079181

General Payments — all program years on this page

$216,099.86

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 86
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $15,799.00 across 4 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
GENZYME CORPORATION $14,518.002
Regeneron Healthcare Solutions, Inc. $1,281.002

By program year

Program yearAmountRecords
2018 $160.843
2019 $15,039.589
2020 $11,070.367
2021 $2,480.001
2022 $60,231.3323
2023 $111,318.7539
2024 $15,799.004

Records — PY2024 (4)

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.